...
首页> 外文期刊>Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique >Preoperative brachytherapy for clinical stage I and II endometrial carcinoma : results from a series of 780 patients with a 10-year follow-up
【24h】

Preoperative brachytherapy for clinical stage I and II endometrial carcinoma : results from a series of 780 patients with a 10-year follow-up

机译:临床I期和II期子宫内膜癌的术前近距离放射疗法:来自780名患者的10年随访结果

获取原文
获取原文并翻译 | 示例
           

摘要

Aims of the study. - Retrospective analysis of patients treated by preoperative brachytherapy for endometrial carcinoma. Patients and methods. - From 1973 to 1994, 780 consecutive patients with a clinical stage I-II endometrial carcinoma were treated with brachytherapy followed by surgery and pelvic irradiation if necessary. Tumour was staged according to 1979 UICC classification. There were 462 T1a, 257 T1b, and 61 T2, 62% were well differentiated. Brachytherapy consisted in one low dose rate endocavitary application. Sixty grays were delivered on the reference isodose. Surgery consisted in a TAH/BSO (Piver II) and was performed 6 weeks later. Nodal pelvic irradiation was indicated in case of unfavourable pathological prognostic factors. Results. - Median follow up was 122 months. Five year survival rates were: 84% for overall survival, 86% for survival without recurrence, 92.8% for local control, and 3.8% for late complications. Pronostic factors were age, stage, differentiation, grade and postoperative extension. Multivariate analysis showed only age, differentiation and postoperative extension to be independent prognostic factors. Conclusion. - If for stage 1, initial surgery has now replaced preoperative brachytherapy in most cases because it allows to identify initial prognostic factors, preoperative brachytherapy remains the most interesting option for stage 2 endometrial carcinomas.
机译:研究目的。 -对术前近距离子宫内膜癌治疗的患者进行回顾性分析。患者和方法。 -从1973年至1994年,连续780例临床分期为I-II期子宫内膜癌的患者接受了近距离放射治疗,然后必要时进行手术和骨盆照射。肿瘤根据1979年UICC分类进行。分别有462个T1a,257个T1b和61个T2,其中62%被很好地区分。近距离放射疗法包括一种低剂量率的腔内应用。在参考等剂量剂量上递送了六十个灰色。手术由TAH / BSO(Piver II)组成,并于6周后进行。如果病理预后不良,则需行盆腔淋巴结照射。结果。 -中位随访时间为122个月。五年生存率是:总生存率84%,无复发生存率86%,局部控制生存率92.8%,晚期并发症生存率3.8%。预后因素是年龄,分期,分化,等级和术后扩展。多因素分析显示只有年龄,分化程度和术后扩展是独立的预后因素。结论。 -如果在第1阶段,由于可以识别最初的预后因素,现在在大多数情况下初始手术已取代术前近距离放射疗法,术前近距离放射疗法仍然是2期子宫内膜癌最有趣的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号